INS and type 2 diabetes mellitus: GLP-1RAs are now advised as the initial choice for injectable glucose-lowering treatments in type 2 diabetes due to their comparable or even better capacity to decrease HbA1c levels, coupled with the benefits of weight loss and a lack of inherent risk for hypoglycemic events, potentially even preceding the use of insulin.